Kailera
Coverage of Kailera in the Nexus archive.
- Kailera's oral weight loss pill met its trial goal, but nausea hit 70% of patients
Kailera's oral weight loss pill HRS-7535 met its trial goal in Phase 3, but 70% of patients experienced nausea. The company's stock dropped 10% following the data release.
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.
- Obesity Treatment Firm Kailera Upsizes IPO to Raise $625 Million
Obesity treatment company Kailera increased its initial public offering (IPO) size to raise $625 million. The firm, which operates a medical laboratory, is expanding its capital-raising efforts to support its operations and growth.